Work

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs21-ot1-10-02

Authors: A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman

Institutions: University of California, San Francisco, Emory University, Winship Cancer Institute, Mayo Clinic, University of Chicago Medical Center, Quantum Leap Healthcare Collaborative, University of Minnesota, Vanderbilt University

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4221032852

Cites:

Cited by: 3

Related to: 10